Home › Companies › MAIA

MAIA Biotechnology

Market cap $77.2M 61.8M shares (10-Q, Nov 9, 2026) × $1.25 close Nov 17, 2026

Most recent annual filing: 2026-03-23

Catalyst timeline

6 trackedQuarter catalyst calendar →
  1. THIO-101 expansion cohort filing2026THIO-101 expansion cohort filing, 2026, material
  2. THIO-102 trial start2026THIO-102 trial start, 2026, notable
  3. THIO-101 Parts C/D corporate update2026THIO-101 Parts C/D corporate update, 2026, notable
  4. THIO-104 Phase 3 Ph3 interim2027THIO-104 Phase 3 Ph3 interim, 2027, material
  5. Wainwright litigation rulingFeb 11, 2027Wainwright litigation ruling, Feb 11, 2027, routine
  6. THIO-104 Ph3 interimmid-2027THIO-104 Ph3 interim, mid-2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Capital (as filed)

Cash
$0K cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$6.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$21.3M cash, runway mid-2027 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Offering documents (5)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (12)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (12 calls)

Every verdict Biotech Distilled has published on MAIA Biotechnology, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Speculative buy speculative Maia Biotechnology (MAIA) - Scientific Deep Dive for Ateganosine and Pipeline Products The mechanism is chemically elegant and Phase 2 survival data is compelling, but near-term dilution and method-of-use patent risks require a speculative position sizing.
  2. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Banker Lawsuit Lands and a Bitcoin Plan Surfaces Clinical thesis intact with dilution gap closed and lawsuit quantified, but a new governance concern — a board-authorized plan to put up to 90% of treasury into crypto — warrants heightened scrutiny.
  3. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Wainwright Divorce Is Final ATM termination removes a dilution lever and is a governance cleanup, but the crypto treasury plan and Tranche 2 financing structure remain unresolved; clinical thesis unchanged.
  4. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The CEO Doubles Down, and a Director Joins Him CEO and director open-market buys are incrementally bullish but governance rakes remain; insider signal is worth noting, not yet worth re-rating.
  5. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The U.S. Door Opens for the Accelerated Approval Cohort FDA clearance of the IND amendment enabling U.S. enrollment in the Accelerated Approval cohort is an incremental operational de-risk, but governance overhang is unchanged.
  6. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Phase 3 Number, and the Interim Slips to 2027 First hard Phase 3 enrollment number is encouraging but the interim analysis has formally slipped to 2027, extending the holding period; Parts C/D ORR is now the closer catalyst.
  7. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - International Part C Enrollment Is Done International Part C enrollment closed with U.S. sites ramping; ORR readout is the next clinically relevant data point, but governance overhang is unchanged.
  8. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - Part C Delivers a 90.5% Disease Control Rate 90.5% DCR in Part C tracks Parts A/B in a harder-to-treat population, retiring the small-N reversion bear case; ORR remains the next key number for Accelerated Approval.
  9. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Burn Rate Catches Up Clinical thesis intact but burn rate stepped up to ~$6.8M/quarter, thinning the runway and bringing a financing conversation into view for 2027; crypto plan still not rescinded.
  10. Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - Part C Is Closed, the Phase 3 Hits 65 Part C enrollment complete and THIO-104 at 65 patients, but a $1M stock-for-trial-funding deal signals the 'fully funded' framing has worn thin and ORR is still missing.
  11. Hold UPDATE: MAIA Biotechnology (MAIA) - The Going-Concern Math Arrives Runway has shrunk to ~3.4 quarters, going-concern language now rests on R&D cost cuts during a pivotal trial, and the next financing looks likely to arrive before the next data catalyst.
  12. Hold UPDATE: MAIA Biotechnology (MAIA) - Another DCR, Still No ORR Pooled 88% DCR is consistent but ORR — the primary endpoint and Accelerated Approval anchor — is still missing; balance sheet unchanged and the 24% pop may invite a dilutive raise.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (43)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Mar 31, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)